Healthcor Management adds Hologic (HOLX) to its portfolio

Hologic (HOLX) : Healthcor Management added new position in Hologic during the most recent quarter end. The investment management firm now holds 4,000,000 shares of Hologic which is valued at $154,720,000 , the company said in a statement filed on Aug 15, 2016 with the SEC.Hologic makes up approximately 8.14% of Healthcor Management’s portfolio.

Other Hedge Funds, Including , Jacobs Levy Equity Management Inc reduced its stake in HOLX by selling 45,660 shares or 45.0% in the most recent quarter. The Hedge Fund company now holds 55,798 shares of HOLX which is valued at $2,158,267. Hologic makes up approx 0.04% of Jacobs Levy Equity Management Inc’s portfolio.Tcw Group Inc boosted its stake in HOLX in the latest quarter, The investment management firm added 550 additional shares and now holds a total of 17,800 shares of Hologic which is valued at $688,504. Mv Capital Management added HOLX to its portfolio by purchasing 57 company shares during the most recent quarter which is valued at $2,205. Conning sold out all of its stake in HOLX during the most recent quarter. The investment firm sold 10,276 shares of HOLX which is valued $382,267.

Hologic opened for trading at $38.39 and hit $38.58 on the upside on Thursday, eventually ending the session at $38.46, with a gain of 0.10% or 0.04 points. The heightened volatility saw the trading volume jump to 16,99,124 shares. Company has a market cap of $10,670 M.

On the company’s financial health, Hologic reported $0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.48. The company had revenue of $717.40 million for the quarter, compared to analysts expectations of $703.38 million. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.

Many Wall Street Analysts have commented on Hologic. Company shares were Reiterated by RBC Capital Mkts on Aug 1, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 39 from a previous price target of $37 .

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.